Litcius/Paper detail

LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

Sara A. Hurvitz, Y.H. Park, Aditya Bardia, Vanesa Quiroga, Vanesa López-Valverde, Jutta Steinseifer, Heather M. Moore, Gonzalo Spera, Cloris Xue, Peter A. Fasching

2021Annals of Oncology18 citationsDOI

Topics & Concepts

AnastrozoleMedicinePalbociclibGynecologyBreast cancerInterim analysisOncologyInternal medicineLetrozoleHER2 negativeCancerTamoxifenMetastatic breast cancerClinical trialAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchCancer Treatment and Pharmacology
LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study | Litcius